Please assess the completion status of the following clinical trial:

Trial Title: Complete Lesion Assessment With ffR and IVUS TechnologY

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
General Inclusion Criteria:~1. Subject's age ≥ 18 years.~2. Subject is an acceptable candidate for percutaneous intervention with the Sponsor's OAS and BA in accordance with their labeled indications and instructions for use.~3. Subject is willing and able to sign an approved informed consent form (ICF).~4. Subject is willing and able to attend follow-up and wound care visits.~General Exclusion Criteria:~1. Subject is pregnant or planning to become pregnant within the study period.~2. Subject is currently participating in an investigational drug or other device study that can clinically interfere with the endpoints of this trial.~3. Subject has a known sensitivity to contrast media and the sensitivity cannot be adequately pre-medicated.~4. Uncontrolled allergy to nitinol, stainless steel, or other stent materials.~5. Subject has known allergy to atherectomy lubricant components such as soybean oil, egg yolk phospholipids, glycerin or sodium hydroxide.~6. Subject has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions.~7. Subject has been diagnosed with chronic renal failure or has a creatinine level \> 2.5, unless on dialysis, prior to the index treatment.~8. Subject has evidence of intracranial or gastrointestinal bleeding within 90 days.~9. Subject has a history of trauma, fracture, major surgery (includes major amputation), or biopsy of a parenchymal organ within past 14 days, or patient has not healed from a previous medical intervention occurring more than 14 days.~10. Subject has a history of stroke or myocardial infarction (MI) within 90 days prior to enrollment in the study.~11. Subject has a planned major surgery (includes major amputation) scheduled within 60 days after treatment of the index limb.~12. Subject has a planned interventional treatment to address stenosis of the contralateral limb scheduled within 60 days after the index treatment.~13. Subject has a planned interventional treatment to address inflow stenosis of the ipsilateral limb scheduled within 60 days after the index treatment.~14. Inflow or bilateral PAD requiring treatment prior to enrollment was not successfully treated, defined as \> 50% residual stenosis and/or occurrence of procedural angiographic complications, excluding dissection types A and B.~15. Subject has previously had their other limb treated as part of the study.~Angiographic Inclusion Criteria:~1. Target lesion(s) located in the anterior tibial (AT), posterior tibial (PT), tibial peroneal trunk (TPT) or peroneal (PR) arteries.~2. Target lesion has ≥ 50 % stenosis by angiography.~3. Subject has a corresponding wound being fed by the target vessel.~Angiographic Exclusion Criteria:~1. Target limb does not have any visual flow to the foot confirmed via distal selective angiography.~2. Thrombus is present or suspected in the target treatment vessel.~3. Target lesion is within a bypass graft or near a previously placed stent.~4. The guide wire cannot be passed across the target lesion.~5. Anterograde access of the lesion is not possible.~6. Subject has angiographic evidence of significant dissection at or near the treatment site.~7. Interventional treatment is intended for in-stent restenosis at the peripheral vascular site.~8. Subject's wound(s) involve multiple angiosomes.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Orbital Atherectomy System (Type: EXPERIMENTAL): Orbital Atherectomy (OA) is performed prior to adjunctive Balloon Angioplasty (BA)
- Balloon Angioplasty (Type: ACTIVE_COMPARATOR): Balloon Angioplasty (BA) alone

Based on this trial design, predict the completion outcome and termination type (if applicable).